April 2023

Plenary #AACR23 New Concepts in Drug Discovery and Engineering - first Jennifer Cochran (Stanford CA) Engineered pr… https://t.co/nnUOazn8vt

8:08am April 19th 2023 via Twitter for iPhone

Ulrich #AACR23 Session 7: tertiary prevention- biomarkers of relapse Session 8: AI and data science - the brave new… https://t.co/L8sKJq7mKG

7:16pm April 18th 2023 via Twitter Web App

Ulrich #AACR23 Session 4: preclinical/clinical partnerships in research: innovative team science; Session 5: health… https://t.co/Iv73k1kluX

7:15pm April 18th 2023 via Twitter Web App

Ulrich #AACR23 Ideas: Session 1, setting the stage for cancer prevention agenda; Session 2: early detection and ear… https://t.co/BAiAujsbMD

7:14pm April 18th 2023 via Twitter Web App

Cornelia Ulrich (Huntsman Cancer Inst UT) #AACR23 A brave new world of cancer prevention. As part of the population… https://t.co/FZzfqwWza4

7:12pm April 18th 2023 via Twitter Web App

Visvanathan #AACR23 The assay 'not good enough to disseminate'; had to develop a 5h test, 1 mL blood, POCT. Scalabl… https://t.co/30PuGUjMbo

7:05pm April 18th 2023 via Twitter Web App

Visvanathan #AACR23 TBCRC-005 prospective biomarker trial results: high CMI (cumulative methylation) at week 4 is a… https://t.co/QvQMliOBl4

7:03pm April 18th 2023 via Twitter Web App

Visvanathan #AACR23 Those you can measure, quantify. Development of panel '22 ref https://t.co/slI66n4yV9 Were thes… https://t.co/UMaNl3mlbk

7:02pm April 18th 2023 via Twitter Web App

Visvanathan #AACR23 Potential clinical utility of DNA methyltation across the breast cancer continuum. atypical hyp… https://t.co/MdMerMqZK8

6:59pm April 18th 2023 via Twitter Web App

Town Hall at #AACR biomarkers and early detection tests for cancer prevention: Kala Visvanathan (Johns Hopkins Univ… https://t.co/NvKoA2tkBJ

6:57pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Indirectly target transc factors by the mediators of the enhancer networks, by targeting SWI/SN… https://t.co/PXZwyqytnV

5:50pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Shows AUC of 80.2% in training of the v2 test. PSA is 0.60. n=743, blinded cohort, 18-transcript… https://t.co/wXnbCdoVe9

5:45pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Improved version with 'MPS-50' with an additional 50 transcripts to improve test, to run on a cu… https://t.co/GZc23SoE0k

5:43pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Have dev a multiplexed urine biomarker for clinically sig prostate cancer TMPRSS2:ERG and lncRNA… https://t.co/FJlSajvdUO

5:42pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Overexp of the gene fusion product ERG, induces prostate cancer in aged mice. One of the first t… https://t.co/vRumIV4pEG

5:34pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Found an imbalance in exons in TEMPRESS2 fused to ERG and ETV1; used 5' RACE to discover, FISH t… https://t.co/6wnKTe1zmR

5:29pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Looked for outlier gene exp, and bioinformatics approach led to discovery of gene fusions in pro… https://t.co/02RBEW4fOP

5:28pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Charles Huggins Nobel Prize winner 1966, androgens are important for prostate ca growth. Discove… https://t.co/lbUq6X7xY7

5:27pm April 18th 2023 via Twitter Web App

Chinnaiyan #AACR23 Chr aberrations in cancer - 1900's hypothesized. Since 2000's, recurrent structural aberrations… https://t.co/bZvVsJKP2j

5:25pm April 18th 2023 via Twitter Web App

Arul Chinnaiyan (Univ Michigan MI) #AACR23 Gene Fusions in solid tumors - implications for precision oncology. On t… https://t.co/xknpu9ME5F

5:22pm April 18th 2023 via Twitter Web App

Rapisarda #AACR23 Q: Both from pt tissue versus PDX, any differences? A: Quite similar, not much variation by seque… https://t.co/nd9Ij3cyix

3:33pm April 18th 2023 via Twitter Web App

Rapisarda #AACR23 Q: Have they been sequenced? A: WES and RNA-Seq. Q: Same media for different organ types? A: Very… https://t.co/dSnxBVZjDf

3:33pm April 18th 2023 via Twitter Web App

Rapisarda #AACR23 Cp to NCI-60: shows similarities, difference of colon adenocarcinoma organoids cp to NCI-60 lines… https://t.co/f4v14NODRY

3:31pm April 18th 2023 via Twitter Web App

Rapisarda #AACR23 PDOrgs <100um, 5% Cultrex RGF BME, Type 2, tested against 166 FDA-approved oncology drugs (100 uM… https://t.co/t1WNEYT

3:26pm April 18th 2023 via Twitter Web App

Rapisarda #AACR23 Has rare and recalcitrant tissue-derived organoids. website: https://t.co/UP5wxfLn63 248 public p… https://t.co/WHCM5MROP3

3:23pm April 18th 2023 via Twitter Web App

Annamaria Rapisarda (Frederick Nat'l Lab for Cancer Research MD) #AACR23 Advancing a screening platform with panels… https://t.co/3z1tZpVcxO

3:22pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Q: What kind of timeline for approval? Medicare reimbursement push you? Diaz: "I think they got… https://t.co/ol6vL6tLkB

1:56pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Diaz 2: Often enrichment tests - 20 pack-years, or genetic predisp, or >45 yo, or sexually activ… https://t.co/BbBZFrj

1:45pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Castle: Great value for low-risk people to relax a bit. Diaz: Low risk is difficult to define. L… https://t.co/muU9jTLfmN

1:44pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Q (from Delphi Dx person) Why not single cancer where there may be more benefit? Spec / Sens tur… https://t.co/ESUn1LHWGB

1:39pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Q: is there a middle ground or wait for years? Castle: Say there may be many tests for many diff… https://t.co/NK9rQhlsNI

1:33pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Bradbury: Luis Diaz commented that 'we may be biting off more than we can chew' and the costs an… https://t.co/hxkSX2xxr8

1:27pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Bradbury: Want to collect data in a registry. Wood: The diagnostic workup is complex. Pathfinder… https://t.co/v9IptU9vhq

1:26pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Castle: NCI knows about 25 MCED tests. Must be another 25 academic centers working on it. LDT pa… https://t.co/2fg5I01NWM

1:21pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Castle pt 2: imaging is also uneven - as far as all organs go. Bradbury: Tumor of origin signal:… https://t.co/3m0eweuarj

1:18pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Castle: About SOC, some SOC tests prevent cancers, e.g. colorectal cancer and cervical cancer sc… https://t.co/QYV1ZdXaM1

1:17pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 Diaz: These are high-risk tests. "It is more like a potential drug." You have to consider the ha… https://t.co/j4zP8MSogJ

1:14pm April 18th 2023 via Twitter Web App

MCED Panel #AACR23 SOC screenings - many individuals are not current. Wood: Had focus groups, clinical trials needs… https://t.co/40zxp0CyvG

1:13pm April 18th 2023 via Twitter Web App

MCED Panel discussion #AACR23 add'l participants: Luis Diaz (Memorial Sloan Kettering NY), Kim Newcomer (Colorectal… https://t.co/b8EuwQXeEJ

1:10pm April 18th 2023 via Twitter Web App

Bradbury #AACR23 For her BRCA carrier patients, have been waiting for something like this, but 'not ready now, hope… https://t.co/d56IgVIbz6

1:08pm April 18th 2023 via Twitter Web App

Bradbury #AACR23 Pt discussion - autonomy, beneficience, justice/equity. HCP's are bound by beneficience, we don't… https://t.co/kvL6UO60Ag

1:06pm April 18th 2023 via Twitter Web App

Bradbury #AACR23 3. Not clear if the tumor of origin data is accurate, very important. 4. Diagnostic odyssey and th… https://t.co/iyD1Dk68ZQ

1:05pm April 18th 2023 via Twitter Web App

Bradbury #AACR23 Shows figure in first reference - two more tests PanSeek and Burning Rock. Stage shifting is not e… https://t.co/qgkrZLmbzZ

1:04pm April 18th 2023 via Twitter Web App